Increased turnover and order intake Net sales increased

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Oct 18, 2013 at 2:45 AM

Increased turnover and order intake

· Net sales increased by 73% to 132.5 (76.5) MSEK · Profit after financial items increased to 7.8 (1.3) MSEK · Earnings per share increased to 1.96 (0.36) SEK · Net profit margin increased to 5.9% (1.7) · Cash at the end of the period was 153.9 (32.5) MSEK (cash includes advanced research grants of approx. 6.0 (8.2) MSEK) · Order intake increased to 17 (12) systems · 15 (7) EBM systems were delivered during the period · Order book at the end of the period was 11 (6) systems · Strategic alliance formed with DiSanto Technology Inc. · Introduction of new EBM system, Arcam Q10 · New share issues have raised a total of 113 MSEK in cash For the third quarter: · Sales increased by 61% to 40.4 (25.1) MSEK · Profit after financial items 0.2 (0.1) MSEK · Order intake amounted to 4 (5) systems · 5 (3) EBM systems were delivered in the third quarter Significant events after the end of September: · Order for EBM-system from GKN in the UK Increased turnover and order intake The strong growth in the second half of 2012 continues and during the first 9 months of 2013 the turnover increased by 73% and the net result was improved significantly, compared to the same period 2012. The strong order intake continues with 17 machine orders in the period, compared with 12 machine orders in the same period of 2012. Trailing 12-month machine orders is 29 systems. The aftermarket is developing well and aftermarket sales in the period were 46.0 MSEK. Strategic alliance with DiSanto Technology The orthopedics market is one of Arcam's two main markets and Arcam’s EBM technology is since 2007 used for industrial manufacturing of orthopedic implants. Advanced orthopedic implants manufactured with Arcam's EBM technology are used by orthopedic surgeons in the US and in Europe. Arcam works long term to further broaden the acceptance and usage of the Arcam EBM technology for the production of orthopedic implants. During the period several new orthopedic products have been launched by Arcam customers. In February, a strategic partnership was formed with the contract manufacturer DiSanto Technology Inc. (DTI) in the U.S. The partnership gives Arcam the ability to offer existing and new customers contract manufacturing of advanced orthopedic implants based on the Arcam EBM technology. The combination of DTI’s knowledge of traditional implant manufacturing and Arcam's cutting-edge Additive Manufacturing technology will accelerate the implant industry’s acceptance of the EBM technology for production of orthopedic implants. Two Arcam Q10 systems were installed at DTI during the period. The agreement with DTI gives Arcam an option to acquire DTI. Introduction of Arcam Q10, for the implant market Arcam Q10 was introduced in March 2013. Arcam Q10 is the first of a new generation of EBM systems, developed for industrial production. Arcam Q10 replaces Arcam A1, which has become an industry standard for Additive Manufacturing of orthopedic implants. Arcam Q10 offers higher productivity and resolution, improved ergonomics, and Arcam LayerQam™, a proprietary and patented camera-based system for quality control of manufactured parts. Arcam Q10 is designed to meet the high standards for efficient volume production of orthopedic implants in an industrial environment. The aerospace market - Important new orders The airline market is a market with very high technical requirements. During the period, we continued to take important machine orders in this market and in particular an order for four systems from an existing customer as well as an order from GPN, received in the beginning of October. The potential in the aerospace industry is very large and intensive efforts are underway to make the company ready for the volumes and requirements in the aviation industry. An important part of this is strict quality assurance and after extensive work our business is now certified to ISO 9001. Private placement of new shares - strong financial position Arcam has high ambitions in two very demanding markets. While both system and aftermarket sales are increasing rapidly and with good margins, increased turnover and activity will require a larger working capital. With a strong financial position, we also have the possibility to exercise the option to acquire DiSanto Technologies. The company raised more than 113 MSEK through private placements during the second quarter. We thus have a financial position that provides us the financial strength needed to continue to grow the company. A strong order book and a positive business situation lays a solid foundation for a strong closing of 2013 and a continued growth in 2014. Mölndal, October 18, 2013 Magnus René, President & CEO The information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published on October 18, 2013 at 08.30 (CET). For further information please contact: Magnus René, CEO Arcam AB Tel: 46 31 710 32 00, alt. cell: 46 702 79 89 99 or E-mail: magnus.rene@arcam.com Arcam provides a cost-efficient Additive Manufacturing solution for production of metal components. The technology offers freedom in design combined with excellent material properties and high productivity. Arcam’s market is global with customers mainly in the orthopedic and aerospace industries. The company was founded in 1997 and is listed on NASDAQ OMX Stockholm, Sweden. Head office and production facilities are located in Mölndal, Sweden. Support offices are located in the US, UK, Italy and China. ________________________________________________________________________________ _ _______ Arcam AB • Krokslätts Fabriker 27A • SE-431 37 Mölndal, Sweden • 46-31-710 32 00 • www.arcam.com

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...